img

Global Antisense Oligonucleotide Therapies Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Antisense Oligonucleotide Therapies Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Due to the COVID-19 pandemic, the global Antisense Oligonucleotide Therapies market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Without GalNAc-conjugated accounting for % of the Antisense Oligonucleotide Therapies global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Genetic Disease segment is altered to an % CAGR throughout this forecast period.
The global key companies of Antisense Oligonucleotide Therapies include Ionis Pharmaceuticals, Sarepta Therapeutics and Nippon Shinyaku, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Antisense Oligonucleotide Therapies market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Antisense Oligonucleotide Therapies landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Antisense Oligonucleotide Therapies market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Antisense Oligonucleotide Therapies market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Antisense Oligonucleotide Therapies market. Readers of the report can become informed about current and future trends of the global Antisense Oligonucleotide Therapies market and how they will impact market growth during the forecast period.



By Company


Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
Segment by Type
Without GalNAc-conjugated
With GalNAc-conjugated

Segment by Application


Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Antisense Oligonucleotide Therapies in global and regional level.
Chapter 3Detailed analysis of Antisense Oligonucleotide Therapies companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense Oligonucleotide Therapies revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Without GalNAc-conjugated
1.2.3 With GalNAc-conjugated
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotide Therapies Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Antisense Oligonucleotide Therapies Market Size (2018-2034)
2.2 Antisense Oligonucleotide Therapies Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Antisense Oligonucleotide Therapies Market Size by Region (2018-2024)
2.4 Global Antisense Oligonucleotide Therapies Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Antisense Oligonucleotide Therapies Countries Ranking by Market Size
3 Antisense Oligonucleotide Therapies Competitive by Company
3.1 Global Antisense Oligonucleotide Therapies Revenue by Players
3.1.1 Global Antisense Oligonucleotide Therapies Revenue by Players (2018-2024)
3.1.2 Global Antisense Oligonucleotide Therapies Market Share by Players (2018-2024)
3.2 Global Antisense Oligonucleotide Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Antisense Oligonucleotide Therapies Revenue
3.4 Global Antisense Oligonucleotide Therapies Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotide Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide Therapies Revenue in 2022
3.5 Global Key Players of Antisense Oligonucleotide Therapies Head office and Area Served
3.6 Global Key Players of Antisense Oligonucleotide Therapies, Product and Application
3.7 Global Key Players of Antisense Oligonucleotide Therapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Antisense Oligonucleotide Therapies Breakdown Data by Type
4.1 Global Antisense Oligonucleotide Therapies Historic Revenue by Type (2018-2024)
4.2 Global Antisense Oligonucleotide Therapies Forecasted Revenue by Type (2024-2034)
5 Global Antisense Oligonucleotide Therapies Breakdown Data by Application
5.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Application (2018-2024)
5.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Antisense Oligonucleotide Therapies Revenue by Company (2021-2024)
6.2 North America Antisense Oligonucleotide Therapies Revenue by Type (2018-2034)
6.3 North America Antisense Oligonucleotide Therapies Revenue by Application (2018-2034)
6.4 North America Antisense Oligonucleotide Therapies Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Antisense Oligonucleotide Therapies Revenue by Company (2021-2024)
7.2 Europe Antisense Oligonucleotide Therapies Revenue by Type (2018-2034)
7.3 Europe Antisense Oligonucleotide Therapies Revenue by Application (2018-2034)
7.4 Europe Antisense Oligonucleotide Therapies Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Antisense Oligonucleotide Therapies Revenue by Company (2021-2024)
8.2 Asia Pacific Antisense Oligonucleotide Therapies Revenue by Type (2018-2034)
8.3 Asia Pacific Antisense Oligonucleotide Therapies Revenue by Application (2018-2034)
8.4 Asia Pacific Antisense Oligonucleotide Therapies Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Antisense Oligonucleotide Therapies Revenue by Company (2021-2024)
9.2 Latin America Antisense Oligonucleotide Therapies Revenue by Type (2018-2034)
9.3 Latin America Antisense Oligonucleotide Therapies Revenue by Application (2018-2034)
9.4 Latin America Antisense Oligonucleotide Therapies Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
9.4.4 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Company (2021-2024)
10.2 Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Type (2018-2034)
10.3 Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Application (2018-2034)
10.4 Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Details
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Products and Services
11.1.4 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue in Antisense Oligonucleotide Therapies Business (2018-2024)
11.1.5 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies SWOT Analysis
11.1.6 Ionis Pharmaceuticals Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Products and Services
11.2.4 Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue in Antisense Oligonucleotide Therapies Business (2018-2024)
11.2.5 Sarepta Therapeutics Antisense Oligonucleotide Therapies SWOT Analysis
11.2.6 Sarepta Therapeutics Recent Development
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Details
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Products and Services
11.3.4 Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue in Antisense Oligonucleotide Therapies Business (2018-2024)
11.3.5 Nippon Shinyaku Antisense Oligonucleotide Therapies SWOT Analysis
11.3.6 Nippon Shinyaku Recent Development
12 Antisense Oligonucleotide Therapies Market Dynamics
12.1 Antisense Oligonucleotide Therapies Industry Trends
12.2 Antisense Oligonucleotide Therapies Market Drivers
12.3 Antisense Oligonucleotide Therapies Market Challenges
12.4 Antisense Oligonucleotide Therapies Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Without GalNAc-conjugated
Table 3. Key Players of With GalNAc-conjugated
Table 4. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 5. Global Antisense Oligonucleotide Therapies Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 6. Global Antisense Oligonucleotide Therapies Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Antisense Oligonucleotide Therapies Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 8. Global Antisense Oligonucleotide Therapies Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 9. Global Antisense Oligonucleotide Therapies Revenue by Players (2018-2024) & (US$ Million)
Table 10. Global Antisense Oligonucleotide Therapies Market Share by Players (2018-2024)
Table 11. Global Top Antisense Oligonucleotide Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapies as of 2022)
Table 12. Ranking of Global Top Antisense Oligonucleotide Therapies Companies by Revenue (US$ Million) in 2022
Table 13. Global 5 Largest Players Market Share by Antisense Oligonucleotide Therapies Revenue (CR5 and HHI) & (2018-2024)
Table 14. Global Key Players of Antisense Oligonucleotide Therapies, Headquarters and Area Served
Table 15. Global Key Players of Antisense Oligonucleotide Therapies, Product and Application
Table 16. Global Key Players of Antisense Oligonucleotide Therapies, Date of Enter into This Industry
Table 17. Mergers & Acquisitions, Expansion Plans
Table 18. Global Antisense Oligonucleotide Therapies Market Size by Type (2018-2024) & (US$ Million)
Table 19. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2018-2024)
Table 20. Global Antisense Oligonucleotide Therapies Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 21. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2024-2034)
Table 22. Global Antisense Oligonucleotide Therapies Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2018-2024)
Table 24. Global Antisense Oligonucleotide Therapies Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2024-2034)
Table 26. North America Antisense Oligonucleotide Therapies Revenue by Company (2021-2024) & (US$ Million)
Table 27. North America Antisense Oligonucleotide Therapies Revenue by Type (2018-2024) & (US$ Million)
Table 28. North America Antisense Oligonucleotide Therapies Revenue by Type (2024-2034) & (US$ Million)
Table 29. North America Antisense Oligonucleotide Therapies Revenue by Application (2018-2024) & (US$ Million)
Table 30. North America Antisense Oligonucleotide Therapies Revenue by Application (2024-2034) & (US$ Million)
Table 31. North America Antisense Oligonucleotide Therapies Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 32. North America Antisense Oligonucleotide Therapies Revenue by Country (2018-2024) & (US$ Million)
Table 33. North America Antisense Oligonucleotide Therapies Revenue by Country (2024-2034) & (US$ Million)
Table 34. Europe Antisense Oligonucleotide Therapies Revenue by Company (2021-2024) & (US$ Million)
Table 35. Europe Antisense Oligonucleotide Therapies Revenue by Type (2018-2024) & (US$ Million)
Table 36. Europe Antisense Oligonucleotide Therapies Revenue by Type (2024-2034) & (US$ Million)
Table 37. Europe Antisense Oligonucleotide Therapies Revenue by Application (2018-2024) & (US$ Million)
Table 38. Europe Antisense Oligonucleotide Therapies Revenue by Application (2024-2034) & (US$ Million)
Table 39. Europe Antisense Oligonucleotide Therapies Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 40. Europe Antisense Oligonucleotide Therapies Revenue by Country (2018-2024) & (US$ Million)
Table 41. Europe Antisense Oligonucleotide Therapies Revenue by Country (2024-2034) & (US$ Million)
Table 42. Asia Pacific Antisense Oligonucleotide Therapies Revenue by Company (2021-2024) & (US$ Million)
Table 43. Asia Pacific Antisense Oligonucleotide Therapies Revenue by Type (2018-2024) & (US$ Million)
Table 44. Asia Pacific Antisense Oligonucleotide Therapies Revenue by Type (2024-2034) & (US$ Million)
Table 45. Asia Pacific Antisense Oligonucleotide Therapies Revenue by Application (2018-2024) & (US$ Million)
Table 46. Asia Pacific Antisense Oligonucleotide Therapies Revenue by Application (2024-2034) & (US$ Million)
Table 47. Asia-Pacific Antisense Oligonucleotide Therapies Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 48. Asia Pacific Antisense Oligonucleotide Therapies Revenue by Region (2018-2024) & (US$ Million)
Table 49. Asia Pacific Antisense Oligonucleotide Therapies Revenue by Region (2024-2034) & (US$ Million)
Table 50. Latin America Antisense Oligonucleotide Therapies Revenue by Company (2021-2024) & (US$ Million)
Table 51. Latin America Antisense Oligonucleotide Therapies Revenue by Type (2018-2024) & (US$ Million)
Table 52. Latin America Antisense Oligonucleotide Therapies Revenue by Type (2024-2034) & (US$ Million)
Table 53. Latin America Antisense Oligonucleotide Therapies Revenue by Application (2018-2024) & (US$ Million)
Table 54. Latin America Antisense Oligonucleotide Therapies Revenue by Application (2024-2034) & (US$ Million)
Table 55. Latin America Antisense Oligonucleotide Therapies Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 56. Latin America Antisense Oligonucleotide Therapies Revenue by Country (2018-2024) & (US$ Million)
Table 57. Latin America Antisense Oligonucleotide Therapies Revenue by Country (2024-2034) & (US$ Million)
Table 58. Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Company (2021-2024) & (US$ Million)
Table 59. Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Type (2018-2024) & (US$ Million)
Table 60. Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Type (2024-2034) & (US$ Million)
Table 61. Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Application (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Application (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Antisense Oligonucleotide Therapies Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 64. Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Country (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Antisense Oligonucleotide Therapies Revenue by Country (2024-2034) & (US$ Million)
Table 66. Ionis Pharmaceuticals Company Details
Table 67. Ionis Pharmaceuticals Business Overview
Table 68. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product and Services
Table 69. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue in Antisense Oligonucleotide Therapies Business (2018-2024) & (US$ Million)
Table 70. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies SWOT Analysis
Table 71. Ionis Pharmaceuticals Recent Development
Table 72. Sarepta Therapeutics Company Details
Table 73. Sarepta Therapeutics Business Overview
Table 74. Sarepta Therapeutics Antisense Oligonucleotide Therapies Product and Services
Table 75. Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue in Antisense Oligonucleotide Therapies Business (2018-2024) & (US$ Million)
Table 76. Sarepta Therapeutics Antisense Oligonucleotide Therapies SWOT Analysis
Table 77. Sarepta Therapeutics Recent Development
Table 78. Nippon Shinyaku Company Details
Table 79. Nippon Shinyaku Business Overview
Table 80. Nippon Shinyaku Antisense Oligonucleotide Therapies Product and Services
Table 81. Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue in Antisense Oligonucleotide Therapies Business (2018-2024) & (US$ Million)
Table 82. Nippon Shinyaku Antisense Oligonucleotide Therapies SWOT Analysis
Table 83. Nippon Shinyaku Recent Development
Table 84. Antisense Oligonucleotide Therapies Market Trends
Table 85. Antisense Oligonucleotide Therapies Market Drivers
Table 86. Antisense Oligonucleotide Therapies Market Challenges
Table 87. Antisense Oligonucleotide Therapies Market Restraints
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Antisense Oligonucleotide Therapies Product Picture
Figure 2. Global Antisense Oligonucleotide Therapies Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Antisense Oligonucleotide Therapies Market Share by Type: 2022 VS 2034
Figure 4. Without GalNAc-conjugated Features
Figure 5. With GalNAc-conjugated Features
Figure 6. Global Antisense Oligonucleotide Therapies Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 7. Global Antisense Oligonucleotide Therapies Market Share by Application: 2022 VS 2034
Figure 8. Genetic Disease
Figure 9. Cancer
Figure 10. Cardiovascular Diseases
Figure 11. Other
Figure 12. Antisense Oligonucleotide Therapies Report Years Considered
Figure 13. Global Antisense Oligonucleotide Therapies Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Antisense Oligonucleotide Therapies Market Size 2018-2034 (US$ Million)
Figure 15. Global Antisense Oligonucleotide Therapies Market Size Market Share by Region: 2022 VS 2034
Figure 16. Global Antisense Oligonucleotide Therapies Revenue Market Share by Region in 2018 VS 2022
Figure 17. Global Antisense Oligonucleotide Therapies Revenue Market Share Forecast by Region (2024-2034)
Figure 18. Global Top 10 Antisense Oligonucleotide Therapies Countries Ranking by Market Size (US$ Million) in 2022
Figure 19. Global Antisense Oligonucleotide Therapies Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 20. Global Antisense Oligonucleotide Therapies Market Share by Players in 2022
Figure 21. Global Top Antisense Oligonucleotide Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapies as of 2022)
Figure 22. The Top 10 and 5 Players Market Share by Antisense Oligonucleotide Therapies Revenue in 2022
Figure 23. North America Antisense Oligonucleotide Therapies Revenue Market Share by Company in 2022
Figure 24. North America Antisense Oligonucleotide Therapies Revenue Market Share by Type (2018-2034)
Figure 25. North America Antisense Oligonucleotide Therapies Revenue Market Share by Application (2018-2034)
Figure 26. North America Antisense Oligonucleotide Therapies Revenue Share by Country (2018-2034)
Figure 27. United States Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 28. Canada Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 29. Europe Antisense Oligonucleotide Therapies Revenue Market Share by Company in 2022
Figure 30. Europe Antisense Oligonucleotide Therapies Revenue Market Share by Type (2018-2034)
Figure 31. Europe Antisense Oligonucleotide Therapies Revenue Market Share by Application (2018-2034)
Figure 32. Europe Antisense Oligonucleotide Therapies Revenue Share by Country (2018-2034)
Figure 33. Germany Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 34. France Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 35. U.K. Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 36. Italy Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 37. Russia Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 38. Asia Pacific Antisense Oligonucleotide Therapies Revenue Market Share by Company in 2022
Figure 39. Asia Pacific Antisense Oligonucleotide Therapies Revenue Market Share by Type (2018-2034)
Figure 40. Asia Pacific Antisense Oligonucleotide Therapies Revenue Market Share by Application (2018-2034)
Figure 41. Asia Pacific Antisense Oligonucleotide Therapies Revenue Share by Region (2018-2034)
Figure 42. China Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 43. Japan Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 44. South Korea Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 45. India Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 46. Australia Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 47. China Taiwan Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 48. Indonesia Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 49. Thailand Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 50. Malaysia Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 51. Latin America Antisense Oligonucleotide Therapies Revenue Market Share by Company in 2022
Figure 52. Latin America Antisense Oligonucleotide Therapies Revenue Market Share by Type (2018-2034)
Figure 53. Latin America Antisense Oligonucleotide Therapies Revenue Market Share by Application (2018-2034)
Figure 54. Latin America Antisense Oligonucleotide Therapies Revenue Share by Country (2018-2034)
Figure 55. Mexico Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 56. Brazil Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 57. Argentina Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 58. Colombia Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 59. Middle East and Africa Antisense Oligonucleotide Therapies Revenue Market Share by Company in 2022
Figure 60. Middle East and Africa Antisense Oligonucleotide Therapies Revenue Market Share by Type (2018-2034)
Figure 61. Middle East and Africa Antisense Oligonucleotide Therapies Revenue Market Share by Application (2018-2034)
Figure 62. Middle East and Africa Antisense Oligonucleotide Therapies Revenue Share by Country (2018-2034)
Figure 63. Turkey Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 64. Saudi Arabia Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 65. UAE Antisense Oligonucleotide Therapies Revenue (2018-2034) & (US$ Million)
Figure 66. Ionis Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotide Therapies Business (2018-2024)
Figure 67. Sarepta Therapeutics Revenue Growth Rate in Antisense Oligonucleotide Therapies Business (2018-2024)
Figure 68. Nippon Shinyaku Revenue Growth Rate in Antisense Oligonucleotide Therapies Business (2018-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed